Investments
120Portfolio Exits
82Funds
1
Want to inform investors similar to Rock Springs Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Rock Springs Capital
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Rock Springs Capital in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Latest Rock Springs Capital News
Sep 8, 2023
Apollo Therapeutics , a Cambridge, UK-, Boston, MA and Chicago, IL-based portfolio biopharmaceutical company, raised $226.5M in Series C funding. The round was led by Patient Square Capital, with participation from new investors including M&G plc along with existing investor Rock Springs Capital. The company intends to use the funds to (i) advance pipeline programs through clinical development and further fund its drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, and to (ii) licence or acquire additional clinical stage programs that meet strict selection criteria. Led by Dr. Richard Mason, CEO, Apollo Therapeutics is a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines. The portfolio-model is built around a centralized management team of capital allocators and functional leaders with expertise in pharmaceutical R&D, manufacturing, commercial strategy, fund-raising, and business development, leveraged over a diverse portfolio of therapeutic programs, each led by a dedicated asset leader. Assets are housed in separate wholly owned subsidiary companies. Current partner institutions are: The University of Cambridge, Imperial College London, University College London, King’s College London, and The Institute of Cancer Research. Apollo has operations in Cambridge, UK, and Boston and Chicago, USA. FinSMEs
Rock Springs Capital Investments
120 Investments
Rock Springs Capital has made 120 investments. Their latest investment was in Apollo Therapeutics as part of their Series C on September 9, 2023.
Rock Springs Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/6/2023 | Series C | Apollo Therapeutics | $226.5M | No | M&G Investments, Patient Square Capital, Rock Springs Capital, and Undisclosed Investors | 5 |
8/21/2023 | Series B | Genesis Therapeutics | $200M | No | Andreessen Horowitz, BlackRock, Fidelity Investments, Menlo Ventures, NVentures, Radical Ventures, Rock Springs Capital, T. Rowe Price, and Undisclosed Investors | 6 |
2/21/2023 | Series B | Hemab | $135M | Yes | 7 | |
12/30/2022 | PIPE | |||||
11/7/2022 | Series B |
Date | 9/6/2023 | 8/21/2023 | 2/21/2023 | 12/30/2022 | 11/7/2022 |
|---|---|---|---|---|---|
Round | Series C | Series B | Series B | PIPE | Series B |
Company | Apollo Therapeutics | Genesis Therapeutics | Hemab | ||
Amount | $226.5M | $200M | $135M | ||
New? | No | No | Yes | ||
Co-Investors | M&G Investments, Patient Square Capital, Rock Springs Capital, and Undisclosed Investors | Andreessen Horowitz, BlackRock, Fidelity Investments, Menlo Ventures, NVentures, Radical Ventures, Rock Springs Capital, T. Rowe Price, and Undisclosed Investors | |||
Sources | 5 | 6 | 7 |
Rock Springs Capital Portfolio Exits
82 Portfolio Exits
Rock Springs Capital has 82 portfolio exits. Their latest portfolio exit was CervoMed on August 16, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
8/16/2023 | Reverse Merger | 3 | |||
7/18/2023 | IPO | Public | 4 | ||
2/10/2023 | IPO | Public | 5 | ||
Date | 8/16/2023 | 7/18/2023 | 2/10/2023 | ||
|---|---|---|---|---|---|
Exit | Reverse Merger | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 3 | 4 | 5 |
Rock Springs Capital Fund History
1 Fund History
Rock Springs Capital has 1 fund, including Rock Springs Capital Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
10/14/2013 | Rock Springs Capital Fund | $101.4M | 1 |
Closing Date | 10/14/2013 |
|---|---|
Fund | Rock Springs Capital Fund |
Fund Type | |
Status | |
Amount | $101.4M |
Sources | 1 |
Rock Springs Capital Team
3 Team Members
Rock Springs Capital has 3 team members, including , .
Name | Work History | Title | Status |
|---|---|---|---|
G. Margraf Bussard | Founder | Current | |
Name | G. Margraf Bussard | ||
|---|---|---|---|
Work History | |||
Title | Founder | ||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
